US 11,866,497 B2
Antibody to fibrosis-related molecule and medical application thereof
Yosuke Kurashima, Tokyo (JP); and Hiroshi Kiyono, Tokyo (JP)
Assigned to The University of Tokyo, Tokyo (JP)
Filed by The University of Tokyo, Tokyo (JP)
Filed on Aug. 11, 2021, as Appl. No. 17/399,725.
Application 17/399,725 is a division of application No. 16/465,253, granted, now 11,117,962, previously published as PCT/JP2017/043348, filed on Dec. 1, 2017.
Claims priority of application No. 2016-234717 (JP), filed on Dec. 2, 2016.
Prior Publication US 2022/0033498 A1, Feb. 3, 2022
Int. Cl. G01N 33/53 (2006.01); C07K 16/28 (2006.01); A61P 29/00 (2006.01); G01N 33/68 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2803 (2013.01) [A61P 29/00 (2018.01); G01N 33/6854 (2013.01); A61K 2039/505 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01)] 6 Claims
 
1. A method for analyzing the presence or absence of inflammation in a tissue in a subject, comprising determining the presence of secreted CHL1 protein in the tissue, a body fluid, or excrement obtained from the subject by using an antibody or an antigen-binding fragment thereof that binds to secreted CHL1 protein,
wherein the antibody and the fragment has a heavy chain variable region having heavy chain CDR1 having the amino acid sequence set forth in SEQ ID NO: 1, heavy chain CDR2 having the amino acid sequence set forth in SEQ ID NO: 2 and heavy chain CDR3 having the amino acid sequence set forth in SEQ ID NO: 3, and a light chain variable region having light chain CDR1 having the amino acid sequence set forth in SEQ ID NO: 5, light chain CDR2 having the amino acid sequence set forth in SEQ ID NO: 6 and light chain CDR3 having the amino acid sequence set forth in SEQ ID NO: 7.